Navigation Links
Timeliness, a Critical Factor in Treating TTTS

It's one of the biggest controversies in fetal surgery and the cause of heated debate among surgeons and maternal-fetal medicine physicians// around the world: What's the best way to treat twin-twin transfusion syndrome (TTTS), one of the most common conditions requiring fetal surgery and the leading cause of mortality in twins?

The benchmark, NIH-funded study on TTTS, conducted at 17 centers in the United States, will be presented February 9 at the annual meeting of the Society for Maternal-Fetal Medicine in San Francisco, and it won't likely resolve the question of which is the best procedure.

The study, led by Timothy Crombleholme, M.D., director of the Fetal Care Center of Cincinnati, shows that the question isn't which surgical procedure is better, it's when the procedure is done.

Dr. Crombleholme issued a clarion call to fetal care specialists around the world. "The earlier in gestation TTTS is diagnosed, the more severe the syndrome tends to be," says Dr. Crombleholme, who is also a pediatric surgeon at Cincinnati Children's Hospital Medical Center.

"We have to shift attention to diagnosing this earlier in the progression of the syndrome and being more aggressive about intervention. We can't conclude that one therapy is better than another, but it's apparent that we're going to compromise survival if treatment isn't initiated before it gets to be severe."

In TTTS, the way in which blood flows through the connecting blood vessels on a shared placenta is unequal. As a result, the donor twin has slowed growth and decreased amniotic fluid, while the recipient has too much amniotic fluid and develops a form of heart failure. Without treatment, TTTS is fatal for at least 90 percent of twins, and both twins are at risk for severe complications.

There are two main treatment modalities: amnioreduction, in which excess amniotic fluid is removed from the recipient twin, or a fetoscopic laser proce dure to treat the anatomic basis for the syndrome. Until now, the only major study comparing these two treatments for TTTS was the Eurofetus trial, which compared laser and amnioreduction as primary therapies. That study, published in The New England Journal of Medicine in 2004, found that, at six months, there was better survival among twins using laser vs. amnioreduction.

The NIH-funded study, which began in 2002, required participants to have more severe disease and to have already failed an initial amnioreduction. But when the Eurofetus results were published, everyone thought that laser was superior and stopped referring patients. The American investigators asked that the trial be stopped. Unbeknownst to investigators at that time, the trial oversight committee found significant differences between the two treatment modalities and recommended that the trial be stopped, which it was in May of 2005.

The trial had uncovered higher mortality among recipient twins who received laser treatment. But overall, survival of one or both twins of the same pregnancy was no different between the two treatments. In addition, there was no difference between survival rates of donor twins and recipient twins. How is this possible?

"It turns out that in amnioreduction, there were significant numbers of treatment failures, so patients were dropping out in the amnioreduction arm because they were failing therapy, whereas they were dying in the laser therapy," says Dr. Crombleholme. Statistically, these patients are considered to have had the same outcome: a treatment failure. So, ultimately, there was no significant difference in survival of one or both twins between the two treatments."

What Dr. Crombleholme and his colleagues did find were two predictors of success. One was the stage of severity of TTTS. The other was the echocardiographic finding of heart failure. Fetal echocardiography, which is not done routinely in TTTS in most c enters, should be done whenever a patient is diagnosed, according to Dr. Crombleholme.

"While one cannot conclude from this study that one therapy is better than the other, neither can one conclude that they're equivalent, because it included patients who failed an initial amnioreduction and then went on to get laser," says Dr. Crombleholme.

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
2. Sleep Not Critical For Early Brain Development Of Baby Dolphins
3. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
4. Dietary supplementation of Folic Acid Requires Critical Evaluation
5. Past President Narayanans Condition Still Critical
6. Critical Decisions Have To Be Taken By Mothers Of Premature Babies
7. Heart Transplant Twin Recovering, But Brother Critical
8. Australia In Search Of A Better Way to Handle Critically Ill Patients and Balance Elective Surgery
9. Yeast Genome Unravels Genes Critical For Maintaining DNA Integrity
10. Drug Trial Goes Foul, Six Volunteers Critically Ill
11. Sensory Input Necessary During "Critical Periods" Of Brain Development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... 24, 2017 , ... HealthPostures, expert standing desk solution designer, ... built into the home office sit stand solution are bold colors, a new ... the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' online ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release of ... in Cannes (France), XO Private has initiated a second print-run of its lavish luxury ... a metre across when open, weighs in at more than six kilos, retails at ...
(Date:2/24/2017)... ... 2017 , ... An in-depth computational analysis of genetic variants implicated in both ... genes that may explain why susceptibility to one of the disorders could place individuals ... today in the journal npj Schizophrenia. , “There is a wealth of genomic ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only ... jobs in the United States may be taken over by technology in the next ... who steamrolls over colleagues is drawing to a close. Success will belong to those ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... disabilities, it is so critically important that we all are aware of our ... why Mediaplanet is proud to announce the launch of its newest edition of ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... Februar 2017 LG Innotek hat heute die ... Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... zwischen 200 und 280 nm und eignet sich damit für ... ihre DNA zerstört. Das Produkt von LG Innotek erzeugt ... ...
Breaking Medicine Technology: